http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102055894-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S514-866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
| filingDate | 2017-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102055894-B1 |
| titleOfInvention | Combination preparation for treating type 2 diabetes mellitus and diabetic dyslipidemia |
| abstract | The present invention relates to a combination formulation for efficiently treating type 2 diabetes mellitus and dyslipidemia in diabetic patients, and more particularly, to peptidase IV inhibitor Gemigliptin or a pharmaceutically acceptable salt thereof and HMG-CoA reduction By providing a co-formulation comprising the enzyme inhibitor rosuvastatin or a pharmaceutically acceptable salt thereof, the present invention relates to efficient glycemic control and cardiovascular risk factor improvement. |
| priorityDate | 2016-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 215.